Improved treatment technology in the fight against prostate cancer is used directly in an ongoing clinical trial
The collaboration between SpectraCure and the German company MedCom GmbH has reached a stage where the technology will be used in SpectraCure's ongoing clinical study. The technology leads to increased precision, accuracy and safety in the treatment of recurrent prostate cancer.
SpectraCure runs an EU-funded development project, together with MedCom GmbH. The purpose of the project is to adapt MedCom's medical imaging technology to SpectraCure's IDOSE treatment planning system, thereby improving IDOSE® and make it more effective. The project has now reached a point where MedCom's system will be used in conjunction with IDOSE directly in patient treatments in SpectraCure's ongoing clinical trial for the treatment of recurrent prostate cancer.
MedCom's system will be used in combination with IDOSE® for patient treatments at University College London Hospital during autumn. In the continued project, MedCom's system will then be integrated with IDOSE® into a joint system, with SpectraCure as the owner and MedCom as a subcontractor.
The treatment method and its strengths
SpectraCure's treatment method is based on the placement of optical fibres that direct laser light to the cancer tumour with great accuracy at predetermined positions in the prostate. Precision positioning is a prerequisite for SpectraCure's IDOSE system to deliver the correct dose to the tumour, without damaging surrounding healthy tissues. Optical fibre needle placement is done using ultrasound imaging.
MedCom uses a more modern imaging and needle navigation system than the technology used by SpectraCure until now. MedCom's technology offers the opportunity to significantly reduce the time for patient treatment, which offers great benefits both for creating acceptance for SpectraCure's treatment method and for reducing healthcare costs.
For further information, please contact:
SpectraCure AB publ, CEO, Masoud Khayyami, phone: +46 (0) 70 815 21 90
Certified Adviser is G&W Fondkommission, e-mail: firstname.lastname@example.org, phone: +46(0) 8 503 000 50
This information is information that SpectraCure AB is required to disclose under the EU Market Abuse Regulation. The information was provided, through the contact of the above contact person, for publication on December 21st, 2019.
SpectraCure in short
SpectraCure was founded in 2003 as a spin off from Lund University departments for medical laser applications and physics. The company focuses on cancer treatments using medical systems with laser light sources and reactive drugs, which is referred to as "Interstitial Photodynamic Therapy", PDT, a treatment methodology suitable for internal solid tumours of various kind, e.g. prostate and abdominal salivary glands, but also other indications such as cancer tumours in the head and neck region